Mangalam Drugs and Organics Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 22, 2025, 9:08 am

Competitors of Mangalam Drugs and Organics Ltd

All Competitor Stocks of Mangalam Drugs and Organics Ltd

Quarterly Result

Last Updated: August 20, 2025, 7:15 am

Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 16.00 Cr..
• For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
• For Operating Profit, as of Jun 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -5.00 Cr., marking a decrease of 15.00 Cr..
• For OPM %, as of Jun 2025, the value is -8.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to -8.00%, marking a decrease of 22.00%.
• For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
• For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to -13.00 Cr., marking a decrease of 15.00 Cr..
• For Tax %, as of Jun 2025, the value is 6.00%. The value appears to be improving (decreasing) as expected. It has decreased from 91.00% (Mar 2025) to 6.00%, marking a decrease of 85.00%.
• For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 14.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is -8.67. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to -8.67, marking a decrease of 8.76.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:53 am

Balance Sheet

Last Updated: October 10, 2025, 2:30 pm

Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 16.00 Cr..
• For Reserves, as of Mar 2025, the value is 133.00 Cr.. The value appears strong and on an upward trend. It has increased from 127.00 Cr. (Mar 2024) to 133.00 Cr., marking an increase of 6.00 Cr..
• For Borrowings, as of Mar 2025, the value is 96.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 107.00 Cr. (Mar 2024) to 96.00 Cr., marking a decrease of 11.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 114.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 108.00 Cr. (Mar 2024) to 114.00 Cr., marking an increase of 6.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 359.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 156.00 Cr.. The value appears strong and on an upward trend. It has increased from 147.00 Cr. (Mar 2024) to 156.00 Cr., marking an increase of 9.00 Cr..
• For CWIP, as of Mar 2025, the value is 3.00 Cr.. The value appears to be declining and may need further review. It has decreased from 8.00 Cr. (Mar 2024) to 3.00 Cr., marking a decrease of 5.00 Cr..
• For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Assets, as of Mar 2025, the value is 201.00 Cr.. The value appears to be declining and may need further review. It has decreased from 202.00 Cr. (Mar 2024) to 201.00 Cr., marking a decrease of 1.00 Cr..
• For Total Assets, as of Mar 2025, the value is 359.00 Cr.. The value appears strong and on an upward trend. It has increased from 357.00 Cr. (Mar 2024) to 359.00 Cr., marking an increase of 2.00 Cr..

Notably, the Reserves (133.00 Cr.) exceed the Borrowings (96.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
• For Diluted EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
• For Cash EPS (Rs.), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 3.52 (Mar 24) to 14.74, marking an increase of 11.22.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 201.05. It has decreased from 232.87 (Mar 24) to 201.05, marking a decrease of 31.82.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 22.95. This value is within the healthy range. It has increased from 11.05 (Mar 24) to 22.95, marking an increase of 11.90.
• For PBIT / Share (Rs.), as of Mar 25, the value is 12.46. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 12.46, marking an increase of 10.66.
• For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has increased from -7.00 (Mar 24) to 3.02, marking an increase of 10.02.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
• For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 4.74 (Mar 24) to 11.41, marking an increase of 6.67.
• For PBIT Margin (%), as of Mar 25, the value is 6.19. This value is below the healthy minimum of 10. It has increased from 0.77 (Mar 24) to 6.19, marking an increase of 5.42.
• For PBT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has increased from -3.00 (Mar 24) to 1.50, marking an increase of 4.50.
• For Net Profit Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 5. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 8. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
• For Return on Networth / Equity (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 15. It has increased from -6.68 (Mar 24) to 4.51, marking an increase of 11.19.
• For Return on Capital Employeed (%), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 11.27, marking an increase of 9.60.
• For Return On Assets (%), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 1.83, marking an increase of 4.54.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 0.64 (Mar 24) to 0.54, marking a decrease of 0.10.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.00 (Mar 24) to 0.90, marking an increase of 0.90.
• For Current Ratio (X), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.04, marking a decrease of 0.03.
• For Quick Ratio (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.31.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.30, marking an increase of 1.30.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 2.43, marking an increase of 1.17.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 0.34 (Mar 24) to 1.45, marking an increase of 1.11.
• For Enterprise Value (Cr.), as of Mar 25, the value is 196.06. It has decreased from 233.41 (Mar 24) to 196.06, marking a decrease of 37.35.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.61, marking a decrease of 0.02.
• For EV / EBITDA (X), as of Mar 25, the value is 5.40. This value is within the healthy range. It has decreased from 13.34 (Mar 24) to 5.40, marking a decrease of 7.94.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
• For Price / BV (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.08 (Mar 24) to 0.78, marking a decrease of 0.30.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
• For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to 0.05, marking an increase of 0.11.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness